Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Outcomes after bone marrow versus peripheral blood mismatched unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMoazzam ShahzadMHMehdi HamadaniRBRajat Bansal

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals no significant survival difference between bone marrow and PBSC grafts in mismatched unrelated donor transplants, suggesting patient factors drive outcomes.

Key Points

  • Bone marrow and peripheral blood stem cell grafts showed similar outcomes in mismatched unrelated donor transplants.
  • Overall survival and disease-free survival did not differ significantly between graft sources after adjustment.
  • Observational analysis of graft outcomes from the CIBMTR dataset from 2017 to 2021 indicates clinical factors are key.
  • Supports individualized transplant planning, highlighting the role of patient age and comorbidities in determining transplant success.

Cite This Study

Shahzad et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dca3https://doi.org/10.1182/blood-2025-934
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025
  2. 2Impact of Conditioning Intensity on Outcomes After Unrelated Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis2025
  3. 3Post-transplant cyclophosphamide based GVHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants2025
  4. 4Factors associated with acute and chronic graft-versus-host disease after unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis2025
  5. 5Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study2025